US stock market predictions and analysis from a team of experienced analysts dedicated to helping you achieve financial success. We combine fundamental analysis, technical indicators, and market sentiment to provide comprehensive stock evaluations.
Ahead of its upcoming fiscal 2026 first-quarter earnings release, Regeneron Pharmaceuticals (NASDAQ: REGN) received a bullish rating update from TD Cowen, which lifted its 12-month price target 9.1% to $960 from $880 while reaffirming a Buy rating. The revision follows the U.S. FDA’s accelerated app
Regeneron Pharmaceuticals (REGN) - TD Cowen Ups Price Target Ahead of Fiscal Q1 Results, Supported by FDA Gene Therapy Approval - Community Risk Signals
REGN - Stock Analysis
4447 Comments
1226 Likes
1
Deliliah
Active Reader
2 hours ago
Real-time US stock event calendar and catalyst tracking for understanding upcoming market-moving announcements. Our event calendar helps you prepare for earnings releases, product launches, and other important dates.
👍 221
Reply
2
Trinidie
Trusted Reader
5 hours ago
This feels like something is missing.
👍 126
Reply
3
Culley
Senior Contributor
1 day ago
Practical insights that can guide thoughtful decisions.
👍 117
Reply
4
Traeveon
Trusted Reader
1 day ago
Too late to act now… sigh.
👍 114
Reply
5
Careen
Returning User
2 days ago
Indices are showing resilience, trading within defined ranges above support levels. Technical indicators suggest continuation potential, while intraday swings remain moderate. Analysts highlight the importance of monitoring volume for trend sustainability.
👍 207
Reply
© 2026 Market Analysis. All data is for informational purposes only.